Estudos WSG-TP-II e MAINTAIN avaliam eficácia da terapia endócrina em diferentes cenários e combinações

Notas do episódio

Referências: Gluz O, Nitz UA, Christgen M, et al. Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial. JAMA Oncol. Published online May 11, 2023. doi:10.1001/jamaoncol.2023.0646 https://jamanetwork.com/journals/jamaoncology/article-abstract/2804892 Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Sakach E, Sathe C, Ahn H, Trivedi MS, Novik Y, Tiersten A, Raptis G, Baer LN, Oh SY, Zelnak AB, Wisinski KB, Andreopoulou E, Gradishar WJ, Stringer-Reasor E, Reid SA, O'Dea A, O'Regan R, Crew KD, Hershman DL. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial. J Clin Oncol. 2023 May 19:JCO2202392. doi: 10.1200/JCO.22.02392. Epub ahead of print. PMID: 37207300. https://ascopubs.org/doi/abs/10.1200/JCO.22.02392